Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. 12 April 2020. Mike Dale.

Executive Summary

Abbott has received two CE marks, expanding access to the company’s TriClip minimally invasive tricuspid valve repair technology and its market-leading Xience everolimus-eluting coronary stent. Mike Dale, senior vice president of Abbott’s structural heart business, explained the significance of the news.

“Tricuspid regurgitation is considered the most undertreated valve issue. Our novel TriClip therapy offers the best possible outcomes for people suffering from a debilitating condition and gives doctors even more options for customizing repair of this complex anatomy." – Mike Dale, senior vice president, structural heart, Abbott

Click here for a free trial of Medtech Insight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel